Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 4:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Comparator: Non-ketone placebo Clear all
Completed Phase 3 Interventional

Comparison of Nicotine Inhaler and/or Bupropion in Helping People to Stop Smoking and Prevent the Recurrence of Smoking

NCT00033592
View directory record Official record
Conditions
Lung Cancer
Interventions
placebo, bupropion hydrochloride, nicotine
Other · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,708 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
24
States / cities
Scottsdale, Arizona • Washington D.C., District of Columbia • Peoria, Illinois + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 7, 2026, 4:00 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Insulin Resistance in Non-alcoholic Fatty Liver Disease

NCT01289639
View directory record Official record
Conditions
Fatty Liver
Interventions
fenofibrate, pioglitazone, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Oct 7, 2026, 4:00 AM EDT
Completed Not applicable Interventional Results available

Obesity and Nonalcoholic Fatty Liver Disease

NCT00262964
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Niacin, fenofibrate, placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 7, 2026, 4:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Tolerance and Safety of a Ketone-Promoting Food Ingredient

NCT04707989
View directory record Official record
Conditions
Tolerance
Interventions
Ketone- Promoting Food Ingredient #1, Ketone- Promoting Food Ingredient #2, Ketone Free Placebo
Other
Lead sponsor
BHB Therapeutics, Ireland LTD
Industry
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 7, 2026, 4:00 AM EDT
Completed Phase 1Phase 2 Interventional

A Preliminary Study of Sustained-Release Bupropion for Smoking Cessation in Bipolar Affective Disorder

NCT00593099
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Bupropion, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 7, 2026, 4:00 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension

NCT00846365
View directory record Official record
Conditions
Essential Hypertension
Interventions
Azilsartan medoxomil and chlorthalidone, Olmesartan medoxomil-hydrochlorothiazide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,085 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
70
States / cities
Birmingham, Alabama • Haleyville, Alabama • Hueytown, Alabama + 67 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Oct 7, 2026, 4:00 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Diabetic Cardiomyopathy and Heart Failure

NCT05571865
View directory record Official record
Conditions
Diabetic Cardiomyopathies, Heart Failure
Interventions
Probiotic
Dietary Supplement
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 7, 2026, 4:00 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension

NCT00818883
View directory record Official record
Conditions
Essential Hypertension
Interventions
Azilsartan medoxomil and chlorthalidone, Azilsartan medoxomil and hydrochlorothiazide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
50
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Scottsboro, Alabama + 47 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2012 · Synced Oct 7, 2026, 4:00 AM EDT
Recruiting Not applicable Interventional

Effects of Ketone Ester Consumption on Exercise Tolerance and Cardiac Function

NCT06078683
View directory record Official record
Conditions
Type 2 Diabetes, Ketone Body Metabolism, Ketones, Metabolism
Interventions
Ketone Ester Acute, Placebo Acute
Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 7, 2026, 4:00 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Exogenous Ketones on Cognitive Function

NCT07051655
View directory record Official record
Conditions
Placebo - Control, Ketone Monoester
Interventions
Ketone Monoester (KE), Placebo
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 7, 2026, 4:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Buck Institute Ketone Ester RCT

NCT05585762
View directory record Official record
Conditions
Tolerance, Safety Issues, Aging
Interventions
Ketone ester, Non-ketone placebo
Other
Lead sponsor
Buck Institute for Research on Aging
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Novato, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 7, 2026, 4:00 AM EDT
Completed Phase 4 Interventional Results available

Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking

NCT00666978
View directory record Official record
Conditions
Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Liver Cancer, Lung Cancer, Pancreatic Cancer, Tobacco Use Disorder
Interventions
smoking cessation intervention, bupropion hydrochloride, gene expression analysis, polymerase chain reaction, counseling intervention, educational intervention, psychosocial assessment and care
Behavioral · Drug · Genetic + 2 more
Lead sponsor
Lisa Sanderson Cox, PhD
Other
Eligibility
18 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
Kansas City, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 7, 2026, 4:00 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation

NCT03110900
View directory record Official record
Conditions
Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use, Lorazepam Causing Adverse Effects in Therapeutic Use, Loxapine Causing Adverse Effects in Therapeutic Use
Interventions
Haloperidol + lorazepam, Loxapine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Oct 7, 2026, 4:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Exogenous Ketones on Indices of Keto-Adaptation in Obese Subjects on Weight Reducing Diets.

NCT06449287
View directory record Official record
Conditions
Ketogenic Diet, Weight Loss
Interventions
Diet, Blood Draw, Ketone/Glucose Monitoring, Body Composition, Urine Analysis, Neuropsychological Measures - ANAM
Other · Biological · Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 7, 2026, 4:00 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

NCT01574703
View directory record Official record
Conditions
Smoking Cessation
Interventions
placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
4,595 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
65
States / cities
Mobile, Alabama • Encino, California • Escondido, California + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 7, 2026, 4:00 AM EDT
Not listed Phase 2 Interventional

Spironolactone in CKD Enabled by Chlorthalidone: PILOT

NCT05222191
View directory record Official record
Conditions
Renal Insufficiency, Chronic Hypertension
Interventions
Spironolactone, Chlorthalidone, Placebo
Drug
Lead sponsor
Indiana Institute for Medical Research
Other
Eligibility
19 Years to 110 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 7, 2026, 4:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Contingent Incentives Plus Bupropion for Smoking in People With Schizophrenia

NCT00136760
View directory record Official record
Conditions
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder
Interventions
Bupropion, Contingent reinforcement plus placebo, non-contingent reinforcement plus bupropion, Non-contingent reinforcement plus placebo
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 80 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Oct 7, 2026, 4:00 AM EDT
Completed Phase 2 Interventional

A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia

NCT01594983
View directory record Official record
Conditions
Non Familial Chylocmicronemia Syndrome (Non-FCS)
Interventions
LCQ908, Fenofibrate, Fish Oil, Placebo of LCQ908, Placebo of fenofibrate, Placebo of fish oil
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Muscle Shoals, Alabama • Glendale, Arizona • Encinitas, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 7, 2026, 4:00 AM EDT
Active, not recruiting Phase 2 Interventional

Combination of Novel Therapies for CKD Comorbid Depression

NCT04422652
View directory record Official record
Conditions
Chronic Kidney Diseases, Major Depressive Disorder, End Stage Kidney Disease (ESRD)
Interventions
Bupropion, Behavioral activation therapy, Placebo, Clinical Management
Drug · Behavioral · Other
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
4
States / cities
Stony Brook, New York • Dallas, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 7, 2026, 4:00 AM EDT
Terminated Phase 3 Interventional

S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery

NCT00032084
View directory record Official record
Conditions
Lung Cancer
Interventions
smoking cessation intervention, bupropion hydrochloride, nicotine, psychosocial assessment and care
Behavioral · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
175
States / cities
Anniston, Alabama • Mobile, Alabama • Phoenix, Arizona + 115 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2013 · Synced Oct 7, 2026, 4:00 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Ketone Conferred Resiliency Against Sleep Restriction With Nutritional Intervention.

NCT06075914
View directory record Official record
Conditions
Sleep Deprivation, Nutritional Intervention
Interventions
Ketogenic Intervention, Mediterranean Intervention, Placebo, Ketone Ester
Other · Dietary Supplement
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 7, 2026, 4:00 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ketone Esters for Appetite, Cognition, and Cardiovascular Function in Individuals With Obesity and Insulin Resistance

NCT05651243
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Ketone Ester Supplement, Placebo
Dietary Supplement · Other
Lead sponsor
University of Southern Mississippi
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Hattiesburg, Mississippi
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 7, 2026, 4:00 AM EDT
Active, not recruiting Phase 3 Interventional

Fenofibrate for Prevention of DR Worsening

NCT04661358
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Fenofibrate, Placebo
Drug · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 80 Years
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
66
States / cities
Glendale, California • Huntington Beach, California • Loma Linda, California + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 7, 2026, 4:00 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Targeting Aging With a Ketone Ester for Function in Frailty

NCT06645847
View directory record Official record
Conditions
Frail Elderly, Aging, Immune Function, Muscle Function
Interventions
Ketone ester, Placebo Comparator: Non-ketone placebo
Other
Lead sponsor
Buck Institute for Research on Aging
Other
Eligibility
65 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
3
States / cities
Novato, California • Farmington, Connecticut • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 7, 2026, 4:00 AM EDT